Controlled drug release liposome composition

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9700511
APP PUB NO 20160030340A1
SERIAL NO

14774833

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TLC BIOPHARMACEUTICALS INC611 GATEWAY BLVD SUITE 830 SOUTH SAN FRANCISCO CA 94080
TAIWAN LIPOSOME COMPANY LTDTAIPEI CITY 11503

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kan, Pei Taipei, TW 27 172
Ou, Han Chun Taipei, TW 1 2
Tseng, Yun-Long Taipei, TW 30 99

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 11, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 11, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00